29
total announcements
AGARWALEYE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹14,834 Cr
P/E (TTM)
100.6
P/E (Forward)
55.6
EPS (TTM)
₹4.65
52W Low
₹401.00
52W High
₹568.00
Dividend Yield
0.00%
Price / Book
7.3
Debt / Equity
50.3
Revenue (TTM)
₹2,207 Cr
Gross Margin
43.61%
Operating Margin
15.00%
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited has issued a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized/rematerialized during the quarter ended June 30, 2026.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited has announced the voting results and Consolidated Scrutinizer's Report on the NCLT convened meeting of the Unsecured Creditors, approving the Scheme of amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited held a meeting of unsecured creditors on July 2, 2026, to consider and approve the Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited with Dr. Agarwal's Health Care Limited. The meeting was adjourned due to lack of quorum, but the resolutions were proposed and voting was conducted through e-voting and polling papers.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited has announced the voting results and Consolidated Scrutinizer's Report on the NCLT convened meeting of the Secured Creditors held on July 02, 2026, approving the Scheme of amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited held a meeting of secured creditors on July 2, 2026, to consider and approve the scheme of amalgamation of Dr. Agarwal's Eye Hospital Limited with Dr. Agarwal's Health Care Limited. The meeting was convened by the National Company Law Tribunal (NCLT) and was attended by 2 secured creditors. The resolution was passed with a special majority as prescribed under Section 230(6) of the Companies Act, 2013.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited has submitted the Exchange a copy of the Scrutinizer's report of the Court Convened General Meeting held on July 02, 2026, and informed the Exchange regarding voting results of the Scheme of amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited held a shareholders meeting on July 02, 2026, to consider and approve the Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited with Dr. Agarwal's Health Care Limited. The meeting was convened by the National Company Law Tribunal (NCLT) and was attended by 47 shareholders, including 17 promoters and 30 public shareholders. The resolution to approve the Scheme was passed with the required quorum.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited has announced the closure of its trading window for designated persons and their immediate relatives, effective from June 30, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure is specifically for the finalization and publication of the company's unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The trading window will reopen 48 hours after these financial results are publicly announced. This is a routine regulatory measure to prevent insider trading before crucial financial information is released to the market.
Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited announced a disclosure submitted under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This filing was made by several associated individuals and trusts, including Dr. Adil Agarwal, Dr. Amar Agarwal, and their respective family trusts. Regulation 31(4) mandates persons acting in concert (PACs) to disclose their aggregate shareholding and voting rights annually. This disclosure enhances transparency for investors, confirming the combined holdings of the identified promoter group and ensuring compliance with takeover regulations.